Axonics Modular Technologies
Novel sacral neuromodulation system for treating overactive bladder
Axonics has developed a novel and potentially best-in-class implantable sacral neuromodulation (SNM) system for the treatment of overactive bladder and faecal incontinence.
It will be the smallest fully implantable, and first rechargeable SNM device, and is expected to work in the body for up to 15 years.
CEO Raymond Cohen
Advent Contact Shahzad Malik
Advent invested in the Series B in 2015.
Exited Investment
U.S. Food and Drug Administration (FDA) accepts New Drug Application for elinzanetant
Press Release. U.S. Food and Drug Administration (FDA) accepts New Drug Application for elinzanetant The New Drug Application (NDA) for elinzanetant, an investigational compound for the treatment of moderate…
Read More
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
Press Release. Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 April 22, 2024 BOSTON and LONDON, April 22, 2024 (GLOBE…
Read More
Advent Life Sciences Announces Growth of Investment Team with Three Senior Appointments
Press Release. 26 May 2022, London, UK: Advent Life Sciences, a leading transatlantic venture and growth investor focused on building innovative life science companies in the UK, Europe, and…
Read More
Advent Life Sciences’ founded Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets
Press Release. This investment will fund Amphista Therapeutics’ growing pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and extend its proprietary platform. London, UK,…
Read More
